This Phase III clinical trial will determine whether adriamycin/taxotere will improve disease- free survival and overall survival when compared to adriamycin/cytoxan (the current standard of therapy), in lymph node positve and high risk lymph node negative breast cancer. The toxicities of the two regimens will be compared.
Showing the most recent 10 out of 470 publications